Skip to main content
. Author manuscript; available in PMC: 2016 Mar 17.
Published in final edited form as: Immunity. 2015 Mar 10;42(3):538–551. doi: 10.1016/j.immuni.2015.02.007

Figure 4. Blocking ICOS inhibits AHR and lung inflammation in RAG2 deficient mice.

Figure 4

A) Rag2−/− mice received 500 μg/mouse anti-mouse ICOS blocking antibody or rat IgG2b (isotype control) on day 1 and received rm-IL-33 or PBS intranasally on day 1 to 3 followed by measurement of lung function, and analyses of bronchoalveolar lavage and lung histology on day 4. B) Lung resistance and C) dynamic compliance. D) Lung histology. E) Total numbers of eosinophils in bronchoalveolar lavage. F) Total number and G) frequency of ILC2s. H) Dot plot of intracellular cytokine production by lung ILC2s after 4 hour of culture in the presence of Brefeldin A. I) Median fluorescence intensity of intracellular IL-5 and IL-13 in lung ILC2s. Data are representative of at least three independent experiments and are presented as mean ± SEM (n=5)(*: P<0.05 anti-ICOS+IL33 compared to isotype+IL33, ###: P<0.005isotype+IL-33 compared to isotype+PBS, ##: P<0.01 isotype+IL-33 compared to isotype+PBS).